Top Story

Adalimumab associated with improvements in nail psoriasis

October 31, 2017
In the Journals

UNCOVER-3: Taltz shows durability over long term

September 28, 2017
Patients with moderate-to-severe plaque psoriasis experienced a durable response to Taltz through 108 weeks, according to results of the UNCOVER-3 trial. The trial…

Expert panel discusses concerns, opportunities surrounding biosimilars in the US

September 27, 2017
Biosimilars remain an unfamiliar and oftentimes controversial topic among physicians in the U.S. Unanswered questions surrounding both the scientific and legislative…
Meeting News

Dupixent improves atopic dermatitis severity in adults

September 25, 2017
Adult patients with moderate to severe atopic dermatitis demonstrated improvements in overall disease severity after treatment with Dupixent, according to findings from…
More Headlines »